Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Neoprobe Corporation (OTC BB:NEOP.OB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Insider | Financials
Location
425 Metro Place North, Suite 300
Dublin, OH 43017
Phone: (614) 793-7500
Fax: (614) 793-7520
Email: info@neoprobe.com
Employees (last reported count): 20
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 21%
·Over the last 6 months:
 · 2 insider sells; 2.19M shares
  (28.6% of insider shares)
·Institutional: 10% (12% of float)
(7 institutions)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Neoprobe Corporation is a developer of gamma-guided surgery dedicated to improving the diagnosis, treatment and quality-of-life of cancer patients. The Company is focused on its two primary technologies, Gamma Detection Systems for Lymphatic Mapping and other applications and the RIGS (radioimmunoguided surgery) Technology. The Company's patented gamma detection systems consist of handheld detector probes and a control unit. The detection device in the tip of the probe is a highly radiosensitive crystal that relays a signal through a preamplifier to the control unit to produce both a digital readout and an audible signal. The RIGS system is an investigational technology that combines a patented handheld gamma radiation detection probe, proprietary disease-specific radio-labeled cancer-targeting agents and a patented surgical method to provide surgeons with real-time information to locate tumor deposits and assist in more thorough removal of the cancer.
More from Market Guide: Expanded Business Description

Financial Summary
NEOP is a development stage enterprise engaged in the development and commercialization of technologies for the diagnosis and treatment of cancers. For the three months ended 3/31/01, net sales decreased 13% to $1.6 million. Net income applicable to Common totaled $81 thousand vs. a loss of $792 thousand. Revenues reflect a decrease in instrument sales. Net income reflects the absence of a $765 thousand loss on the retirement of preferred stock.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 2,277; after tax earnings were 177. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Julius Krevans, M.D., 76
Chairman
--  
David Bupp, 51
Pres, CEO
$553K
Brent Larson, 37
CFO, VP-Fin., Treasurer, Assistant Sec.
229K
Carl Bosch, 44
VP, Instrument Devel.
233K
Rodger Brown, 50
VP, Regulatory Affairs and Quality Assurance
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- OTC BB:NEOP.OBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 29-Dec-2000
$0.375
Recent Price$0.44 
52-Week High
on 11-June-2001
$1.05 
Beta-0.38 
Daily Volume (3-month avg)111.7K
Daily Volume (10-day avg)36.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-41.3%
52-Week Change
relative to S&P500
-21.3%
Share-Related Items
Market Capitalization$11.6M
Shares Outstanding26.3M
Float20.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.12 
Earnings (ttm)$0.06 
Earnings (mrq)$0.01 
Sales (ttm)$0.37 
Cash (mrq*)$0.14 
Valuation Ratios
Price/Book (mrq*)3.79 
Price/Earnings (ttm)7.59 
Price/Sales (ttm)1.19 
Income Statements
Sales (ttm)$9.04M
EBITDA (ttm*)$1.37M
Income available to common (ttm)$1.49M
Profitability
Profit Margin (ttm)16.4%
Operating Margin (ttm)14.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)20.90%
Return on Equity (ttm)59.47%
Financial Strength
Current Ratio (mrq*)2.90 
Debt/Equity (mrq*)0.03 
Total Cash (mrq)$4.47M
Short Interest
As of 8-July-1999
Shares Short520.0K
Percent of Float3.8%
Shares Short
(Prior Month)
545.0K
Short Ratio7.03 
Daily Volume74.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.